Brought to you by 
Roche nets $1.89bn in Genentech offering
17 Jul 2015
Executive Summary
One month after buying out Genentech, Roche brought the company to the marketplace in an IPO consisting of 20mm common shares at $97 apiece, netting a total of about $1.89bn. The offering, the largest the biotech industry has seen, also includes a 2mm-share underwriter option, and represents roughly 16% of Roche's total Genentech holdings, leaving Roche with post-IPO ownership of 83%.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
- Spin-Off
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche nets $1.89bn in Genentech offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice